Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 clinical trial of RES-010 in obesity patients

Next Previous
Trial Profile

A Phase 2 clinical trial of RES-010 in obesity patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RES-010 (Primary)
  • Indications Obesity
  • Focus Proof of concept; Therapeutic Use

Most Recent Events

  • 28 Oct 2024 According to a Resalis Therapeutics media release, company announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010, through a Phase 2 proof-of-concept clinical trial.
  • 09 Jan 2024 New trial record
  • 04 Jan 2024 According to a Resalis Therapeutics media release, company announced today closing of a 11 million Euro Series A financing round and the proceeds will be used for Phase 2 RES-010 program in obesity.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top